<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2018-07-11" updated="2019-12-02">
  <drugbank-id primary="true">DB14502</drugbank-id>
  <drugbank-id>DBSALT001976</drugbank-id>
  <name>Sodium phosphate, dibasic</name>
  <description/>
  <cas-number>7558-79-4</cas-number>
  <unii>22ADO53M6F</unii>
  <average-mass>141.9588</average-mass>
  <monoisotopic-mass>141.940784382</monoisotopic-mass>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A19446</ref-id>
        <pubmed-id>17652123</pubmed-id>
        <citation>Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24.</citation>
      </article>
      <article>
        <ref-id>A19447</ref-id>
        <pubmed-id>18645612</pubmed-id>
        <citation>Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521.</citation>
      </article>
      <article>
        <ref-id>A19448</ref-id>
        <pubmed-id>19298584</pubmed-id>
        <citation>Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27.</citation>
      </article>
      <article>
        <ref-id>A19449</ref-id>
        <pubmed-id>20958267</pubmed-id>
        <citation>Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377.</citation>
      </article>
      <article>
        <ref-id>A19450</ref-id>
        <pubmed-id>23398154</pubmed-id>
        <citation>Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L798</ref-id>
        <title>FDA Guide: Sodium Phosphate Tablet</title>
        <url>https://www.fda.gov/downloads/drugs/drugsafety/ucm134684.pdf</url>
      </link>
      <link>
        <ref-id>L799</ref-id>
        <title>ChemIDPlus: Sodium Phosphate</title>
        <url>https://chem.nlm.nih.gov/chemidplus/rn/7558-80-7</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Used to treat constipation or to clean the bowel before a colonoscopy [FDA Label].</indication>
  <pharmacodynamics>Sodium phosphate inceases fecal water content to increase mobility through the large intestine [A19446].</pharmacodynamics>
  <mechanism-of-action>Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen [A19446].</mechanism-of-action>
  <toxicity>Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats [L799]. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma [A19449]. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients [A19448].</toxicity>
  <metabolism/>
  <absorption>Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h [A19448].</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.</description>
    <direct-parent>Alkali metal phosphates</direct-parent>
    <kingdom>Inorganic compounds</kingdom>
    <superclass>Mixed metal/non-metal compounds</superclass>
    <class>Alkali metal oxoanionic compounds</class>
    <subclass>Alkali metal phosphates</subclass>
    <alternative-parent>Inorganic oxides</alternative-parent>
    <alternative-parent>Inorganic sodium salts</alternative-parent>
    <substituent>Alkali metal phosphate</substituent>
    <substituent>Inorganic oxide</substituent>
    <substituent>Inorganic salt</substituent>
    <substituent>Inorganic sodium salt</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001974</drugbank-id>
      <name>Sodium phosphate, dibasic dihydrate</name>
      <unii>94255I6E2T</unii>
      <cas-number>10028-24-7</cas-number>
      <inchikey>KDQPSPMLNJTZAL-UHFFFAOYSA-L</inchikey>
      <average-mass>177.987</average-mass>
      <monoisotopic-mass>177.96191344</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001975</drugbank-id>
      <name>Sodium phosphate, dibasic dodecahydrate</name>
      <unii>E1W4N241FO</unii>
      <cas-number>10039-32-4</cas-number>
      <inchikey>DGLRDKLJZLEJCY-UHFFFAOYSA-L</inchikey>
      <average-mass>358.137</average-mass>
      <monoisotopic-mass>358.06756028</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001977</drugbank-id>
      <name>Sodium phosphate, dibasic, heptahydrate</name>
      <unii>70WT22SF4B</unii>
      <cas-number>7782-85-6</cas-number>
      <inchikey>PYLIXCKOHOHGKQ-UHFFFAOYSA-L</inchikey>
      <average-mass>268.062</average-mass>
      <monoisotopic-mass>268.01473686</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001973</drugbank-id>
      <name>Sodium phosphate, dibasic, monohydrate</name>
      <unii>BWZ7K44R51</unii>
      <cas-number>118830-14-1</cas-number>
      <inchikey>LVXHNCUCBXIIPE-UHFFFAOYSA-L</inchikey>
      <average-mass>159.972</average-mass>
      <monoisotopic-mass>159.95134875</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Dibasic sodium phosphate anhydrous</synonym>
    <synonym language="english" coder="">Dibasic sodium phosphate, anhydrous</synonym>
    <synonym language="english" coder="">Disodium acid phosphate</synonym>
    <synonym language="english" coder="">Disodium hydrogen monophosphate</synonym>
    <synonym language="english" coder="">Disodium hydrogen phosphate</synonym>
    <synonym language="english" coder="">Disodium hydrogen phosphate, anhydrous</synonym>
    <synonym language="english" coder="iupac">disodium hydrogenphosphate</synonym>
    <synonym language="english" coder="">Disodium phosphate</synonym>
    <synonym language="english" coder="">Phosphoric acid, disodium salt, anhydrous</synonym>
    <synonym language="english" coder="">Phosphoric acid, sodium salt (1:2)</synonym>
    <synonym language="english" coder="">Sodium phosphate dibasic</synonym>
    <synonym language="english" coder="">Sodium phosphate, dibasic</synonym>
    <synonym language="english" coder="">Sodium phosphate, dibasic (anhydrous)</synonym>
    <synonym language="english" coder="">Sodium phosphate, dibasic anhydrous</synonym>
    <synonym language="english" coder="">Sodium phosphate, dibasic, anhydrous</synonym>
    <synonym language="english" coder="">Sodium phosphate,dibasic,anhydrous</synonym>
  </synonyms>
  <products>
    <product>
      <name>Aminosyn II 7% M In 10% Dextrose(dual Chamber)</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00742724</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2012-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00742716</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2012-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aminosyn II and Dextrose</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-7742</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1988-11-01</started-marketing-on>
      <ended-marketing-on>2010-01-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA019682</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Amo Endosol Extra</name>
      <labeller>Amo Canada Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01992546</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2008-07-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intraocular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Av-Phos 250 Neutral</name>
      <labeller>AvKARE, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-152</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bss Plus</name>
      <labeller>Alcon, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00568082</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Solution</dosage-form>
      <strength/>
      <route>Intraocular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-03-11</started-marketing-on>
      <ended-marketing-on>2018-06-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>Rising Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64980-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-2195</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-7676</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-06-28</started-marketing-on>
      <ended-marketing-on>2018-05-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>Kaiser Foundations Hospitals</labeller>
      <ndc-id/>
      <ndc-product-code>0179-0154</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-764</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-13</started-marketing-on>
      <ended-marketing-on>2020-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eyesaline Eyewash</name>
      <labeller>Fendall, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01988220</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-16</started-marketing-on>
      <ended-marketing-on>2005-08-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Irrigation</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0546</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0549</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0531</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-11-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0528</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0545</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0539</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0525</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0530</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-0826</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>part334</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0541</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0527</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0532</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>part334</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0553</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0534</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0544</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0542</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1954-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0537</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0538</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-05-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0536</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0543</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet for Children</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0535</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-02-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet for Children</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0529</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-08-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet for Children</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0526</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet for Children</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet for Children</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0207</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fleet for Children</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0552</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fucidin Leo Injection Kit</name>
      <labeller>Leo Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02049406</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on>2004-08-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gent-L-tip Phosphate Enema</name>
      <labeller>Chester Packaging</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00528463</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on>2001-09-26</ended-marketing-on>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Glycerolyte 57 Solution</name>
      <labeller>Fresenius Kabi Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00783668</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Unknown</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Heparin Sodium 1000units In 0.9% Sodium Chloride Injection USP</name>
      <labeller>B. Braun Medical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01935933</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Heparin Sodium In 5% Dextrose Injection, 25000unit/500ml</name>
      <labeller>B. Braun Medical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01935941</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Isolyte S Ph 7.4 (multi-electrolyte Injection)</name>
      <labeller>B. Braun Medical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01931679</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-09-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>K Phos Neutral</name>
      <labeller>Beach Products, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0486-1125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Moi-stir Oral Swabsticks</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238697</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on>2004-08-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Buccal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Moi-stir Oral Swabsticks</name>
      <labeller>Solvay Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01944371</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1997-12-24</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Buccal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Moi-stir Spray</name>
      <labeller>Solvay Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01944428</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1997-12-24</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Buccal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Monobasic Sodium Phosphate and Dibasic Sodium Phosphate</name>
      <labeller>Novel Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40032-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>ANDA079247</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Navstel</name>
      <labeller>Alcon, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02375109</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Solution</dosage-form>
      <strength/>
      <route>Intraocular; Irrigation</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Neutralite Liq</name>
      <labeller>Canadian Custom Packaging Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00313467</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1964-12-31</started-marketing-on>
      <ended-marketing-on>2012-11-20</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Normo Gastryl</name>
      <labeller>Sabex Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00570826</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1973-12-31</started-marketing-on>
      <ended-marketing-on>2009-11-24</ended-marketing-on>
      <dosage-form>Tablet, effervescent</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>OsmoPrep</name>
      <labeller>Salix Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>65649-701</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021892</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>OsmoPrep</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5889</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021892</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pedia-Lax</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0132-0202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>part334</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Phospho-soda Buffered Saline Laxative</name>
      <labeller>C.B. Fleet Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00771678</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1998-12-28</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Phospho-Trin 250 Neutral</name>
      <labeller>Patrin Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>39328-107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Phoxillum B22k4/0</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>24571-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA207026</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Phoxillum Bk4/2.5</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>24571-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA207026</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PMS-phosphates Solution</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01986147</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-07</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Relief</name>
      <labeller>Leosons Overseas Corp</labeller>
      <ndc-id/>
      <ndc-product-code>69626-0084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>part334</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>American Regent</labeller>
      <ndc-id/>
      <ndc-product-code>0517-3450</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2013-10-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5738</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2018-06-25</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>H and P Industries, Inc. dba Triad Group</labeller>
      <ndc-id/>
      <ndc-product-code>50730-2111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-05-22</started-marketing-on>
      <ended-marketing-on>2010-05-31</ended-marketing-on>
      <dosage-form>Enema</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number>part334</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>American Regent</labeller>
      <ndc-id/>
      <ndc-product-code>0517-3415</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2016-04-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-170</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>American Regent</labeller>
      <ndc-id/>
      <ndc-product-code>0517-3405</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-09-30</started-marketing-on>
      <ended-marketing-on>2013-06-01</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-7391</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA018892</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sodium Phosphates Injection USP</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00896187</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Solution Saline Sterile Aux Phosphates</name>
      <labeller>Omega Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00616958</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ssp+</name>
      <labeller>Maco Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02492075</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ssp+</name>
      <labeller>Maco Pharma</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02492067</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Super Charged Energy</name>
      <labeller>Simone Protective Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230209</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tis-U-sol</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-0190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-02-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Irrigant</dosage-form>
      <strength/>
      <route>Irrigation</route>
      <fda-application-number>NDA018508</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tis-U-Sol</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0338-0189</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-10-06</started-marketing-on>
      <ended-marketing-on>2006-04-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Irrigation</route>
      <fda-application-number>NDA018336</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tis-U-sol Solution</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00800007</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Irrigation</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Virt Phos 250 Neutral</name>
      <labeller>Virtus Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>76439-268</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-13</started-marketing-on>
      <ended-marketing-on>2017-04-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Virt-Phos 250 Neutral</name>
      <labeller>Virtus Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>69543-268</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Visicol</name>
      <labeller>Salix Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>65649-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-10-01</started-marketing-on>
      <ended-marketing-on>2012-02-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021097</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Visicol</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5396</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-08-24</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>NDA021097</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Fucidin Leo Injection Kit</name>
      <ingredients>Fusidic acid</ingredients>
    </mixture>
    <mixture>
      <name>OsmoPrep</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Monobasic Sodium Phosphate and Dibasic Sodium Phosphate</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Visicol</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Aminosyn II and Dextrose</name>
      <ingredients>Alanine + Arginine + Aspartic acid + D-glucose + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium chloride + Methionine + N-acetyltyrosine + Phenylalanine + Potassium chloride + Proline + Serine + Sodium chloride + Sodium phosphate, dibasic + Threonine + Tryptophan + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Tis-U-Sol</name>
      <ingredients>Magnesium sulfate + Monopotassium phosphate + Potassium chloride + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Visicol</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Relief</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Pedia-Lax</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Tis-U-sol</name>
      <ingredients>Magnesium sulfate + Monopotassium phosphate + Potassium chloride + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Fleet for Children</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet for Children</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet for Children</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet for Children</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet for Children</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet for Children</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Av-Phos 250 Neutral</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Virt-Phos 250 Neutral</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Fleet</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic, unspecified form</ingredients>
    </mixture>
    <mixture>
      <name>Virt Phos 250 Neutral</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Phospho-Trin 250 Neutral</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>OsmoPrep</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>K Phos Neutral</name>
      <ingredients>Monopotassium phosphate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Phoxillum Bk4/2.5</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Phoxillum B22k4/0</name>
      <ingredients>Magnesium chloride + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Tis-U-sol Solution</name>
      <ingredients>Magnesium sulfate + Monopotassium phosphate + Potassium chloride + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Phosphates Injection USP</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Heparin Sodium In 5% Dextrose Injection, 25000unit/500ml</name>
      <ingredients>Citric acid + Dextrose, unspecified form + Heparin + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Isolyte S Ph 7.4 (multi-electrolyte Injection)</name>
      <ingredients>Gluconic Acid + Magnesium chloride + Monopotassium phosphate + Potassium chloride + Sodium acetate + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Bss Plus</name>
      <ingredients>Calcium chloride + Dextrose, unspecified form + Glutathione disulfide + Magnesium chloride + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Moi-stir Spray</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Moi-stir Oral Swabsticks</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>PMS-phosphates Solution</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Phospho-soda Buffered Saline Laxative</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Amo Endosol Extra</name>
      <ingredients>Calcium chloride + Dextrose, unspecified form + Glutathione disulfide + Magnesium chloride + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Neutralite Liq</name>
      <ingredients>Chlorobutanol + Monopotassium phosphate + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Eyesaline Eyewash</name>
      <ingredients>Sodium chloride + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Normo Gastryl</name>
      <ingredients>Sodium bicarbonate + Sodium phosphate, dibasic + Sodium sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Gent-L-tip Phosphate Enema</name>
      <ingredients>Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Moi-stir Oral Swabsticks</name>
      <ingredients>Calcium chloride + Magnesium chloride + Potassium chloride + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Navstel</name>
      <ingredients>Calcium chloride + Dextrose, unspecified form + Glutathione disulfide + Hypromellose + Magnesium chloride + Potassium chloride + Sodium bicarbonate + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Dextrose, unspecified form + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium chloride + Methionine + N-acetyltyrosine + Phenylalanine + Potassium chloride + Proline + Serine + Sodium chloride + Sodium phosphate, dibasic + Threonine + Tryptophan + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Aminosyn II 7% M In 10% Dextrose(dual Chamber)</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Dextrose, unspecified form + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium chloride + Methionine + N-acetyltyrosine + Phenylalanine + Potassium chloride + Proline + Serine + Sodium chloride + Sodium phosphate, dibasic + Threonine + Tryptophan + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Heparin Sodium 1000units In 0.9% Sodium Chloride Injection USP</name>
      <ingredients>Citric acid + Heparin + Sodium chloride + Sodium phosphate, dibasic</ingredients>
    </mixture>
    <mixture>
      <name>Solution Saline Sterile Aux Phosphates</name>
      <ingredients>Sodium chloride + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Glycerolyte 57 Solution</name>
      <ingredients>Glycerin + Lactic acid + Potassium chloride + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Super Charged Energy</name>
      <ingredients>Ascorbic acid + Beta carotene + Biotin + Calcium + Cholecalciferol + Cyanocobalamin + Folic acid + Magnesium + Nicotinamide + Pantothenic acid + Potassium + Potassium chloride + Pyridoxine + Riboflavin + Sodium phosphate, dibasic + Thiamine + Vitamin A + Vitamin E</ingredients>
    </mixture>
    <mixture>
      <name>Ssp+</name>
      <ingredients>Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
    <mixture>
      <name>Ssp+</name>
      <ingredients>Magnesium chloride + Potassium chloride + Sodium acetate + Sodium chloride + Sodium citrate + Sodium phosphate, dibasic + Sodium phosphate, monobasic</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids</category>
      <mesh-id>D000143</mesh-id>
    </category>
    <category>
      <category>Acids, Noncarboxylic</category>
      <mesh-id>D000148</mesh-id>
    </category>
    <category>
      <category>Anions</category>
      <mesh-id>D000838</mesh-id>
    </category>
    <category>
      <category>Electrolytes</category>
      <mesh-id>D004573</mesh-id>
    </category>
    <category>
      <category>Ions</category>
      <mesh-id>D007477</mesh-id>
    </category>
    <category>
      <category>Laxatives</category>
      <mesh-id>D054368</mesh-id>
    </category>
    <category>
      <category>Osmotic Laxatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Phosphoric Acids</category>
      <mesh-id>D010756</mesh-id>
    </category>
    <category>
      <category>Phosphorus Acids</category>
      <mesh-id>D017976</mesh-id>
    </category>
    <category>
      <category>Phosphorus Compounds</category>
      <mesh-id>D017553</mesh-id>
    </category>
    <category>
      <category>Urinary Acidifying Agents</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intraocular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; solution</form>
      <route>Intraocular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Unknown</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Buccal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Buccal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; solution</form>
      <route>Intraocular; Irrigation</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, effervescent</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Enema</form>
      <route>Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Respiratory (inhalation)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Irrigant</form>
      <route>Irrigation</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Irrigation</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Irrigation</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents>
    <patent>
      <number>7687075</number>
      <country>United States</country>
      <approved>2010-03-30</approved>
      <expires>2028-06-22</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Sodium phosphate, dibasic may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Sodium phosphate, dibasic may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tramadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Trospium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Oxyphenonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Benzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amitriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Ipratropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Metixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Terfenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Buclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Doxylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Trihexyphenidyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Oxyphencyclimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Procyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Profenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Hyoscyamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Cyproheptadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Imipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Methscopolamine bromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Gallamine triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Darifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tridihexethyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Anisotropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nortriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Lamotrigine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Atropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Pirenzepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Homatropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Rocuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Benzquinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Clidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Propiomazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Propantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dicyclomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Biperiden.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Brompheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Maprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Cycrimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Glycopyrronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tolterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Doxacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Doxepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Flavoxate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Diphenidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Isopropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Mepenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Fesoterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Hexocyclium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dimetindene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dexetimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Chlorphenoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Umeclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Trimebutine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Imidafenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Butylscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Thonzylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Methscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Revefenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Oxitropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Propiverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Batefenterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tropatepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Prifinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Piperidolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Benzilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Difemerine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Phenglutarimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Mazaticol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Etybenzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Emepronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Poldine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Bevonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Rociverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Bornaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Etanautine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tiemonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dihexyverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Penthienate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Diphemanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Camylofin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Fenpiverinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Emetonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Pipenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Timepidium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The serum concentration of Amphetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The serum concentration of Phentermine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The serum concentration of Pseudoephedrine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The serum concentration of Benzphetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The serum concentration of Diethylpropion can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The serum concentration of Lisdexamfetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The serum concentration of Mephentermine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The serum concentration of MMDA can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The serum concentration of Midomafetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The serum concentration of Tenamfetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The serum concentration of Chlorphentermine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The serum concentration of Methylenedioxyethamphetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The serum concentration of Dextroamphetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The serum concentration of Metamfetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The serum concentration of Iofetamine I-123 can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The serum concentration of Ritobegron can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The serum concentration of Mephedrone can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The serum concentration of Methoxyphenamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The serum concentration of Gepefrine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The risk or severity of adverse effects can be increased when Torasemide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>The risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The risk or severity of adverse effects can be increased when Triamterene is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The risk or severity of adverse effects can be increased when Metolazone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The risk or severity of adverse effects can be increased when Benzthiazide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>The risk or severity of adverse effects can be increased when Amiloride is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Cyclothiazide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The risk or severity of adverse effects can be increased when Furosemide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>The risk or severity of adverse effects can be increased when Eplerenone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Methazolamide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The risk or severity of adverse effects can be increased when Mannitol is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The risk or severity of adverse effects can be increased when Indapamide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The risk or severity of adverse effects can be increased when Conivaptan is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of adverse effects can be increased when Bumetanide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of adverse effects can be increased when Zonisamide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The risk or severity of adverse effects can be increased when Diazoxide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>The risk or severity of adverse effects can be increased when Diclofenamide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The risk or severity of adverse effects can be increased when Polythiazide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The risk or severity of adverse effects can be increased when Quinethazone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The risk or severity of adverse effects can be increased when Drospirenone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The risk or severity of adverse effects can be increased when Theobromine is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>The risk or severity of adverse effects can be increased when Piretanide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>The risk or severity of adverse effects can be increased when Tienilic acid is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05034</drugbank-id>
      <name>Ularitide</name>
      <description>The risk or severity of adverse effects can be increased when Ularitide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The risk or severity of adverse effects can be increased when Tolvaptan is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The risk or severity of adverse effects can be increased when Indisulam is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>The risk or severity of adverse effects can be increased when Azosemide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09015</drugbank-id>
      <name>Canrenoic acid</name>
      <description>The risk or severity of adverse effects can be increased when Canrenoic acid is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Empagliflozin is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The risk or severity of adverse effects can be increased when Potassium citrate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The risk or severity of adverse effects can be increased when Efonidipine is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09338</drugbank-id>
      <name>Mersalyl</name>
      <description>The risk or severity of adverse effects can be increased when Mersalyl is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>The risk or severity of adverse effects can be increased when Isosorbide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Ertugliflozin is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12221</drugbank-id>
      <name>Canrenone</name>
      <description>The risk or severity of adverse effects can be increased when Canrenone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12670</drugbank-id>
      <name>Rolofylline</name>
      <description>The risk or severity of adverse effects can be increased when Rolofylline is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12704</drugbank-id>
      <name>Spiradoline</name>
      <description>The risk or severity of adverse effects can be increased when Spiradoline is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>The risk or severity of adverse effects can be increased when Cicletanine is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>The risk or severity of adverse effects can be increased when Meticrane is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>The risk or severity of adverse effects can be increased when Ibopamine is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>The risk or severity of adverse effects can be increased when Mefruside is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>The risk or severity of adverse effects can be increased when Mebutizide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>The risk or severity of adverse effects can be increased when Clorexolone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>The risk or severity of adverse effects can be increased when Clofenamide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>The risk or severity of adverse effects can be increased when Fenquizone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>The risk or severity of adverse effects can be increased when Clopamide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>The risk or severity of adverse effects can be increased when Muzolimine is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>The risk or severity of adverse effects can be increased when Xipamide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>The risk or severity of adverse effects can be increased when Epitizide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The risk or severity of adverse effects can be increased when Bromotheophylline is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Trimethadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nisoldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Lercanidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Cinnarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Ethosuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Magnesium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Loperamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Perhexiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Prenylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04838</drugbank-id>
      <name>Cyclandelate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Cyclandelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Methsuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05885</drugbank-id>
      <name>Seletracetam</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Seletracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nylidrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Ziconotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dotarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Xylometazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tranilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08162</drugbank-id>
      <name>Fasudil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Fasudil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Agmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Fendiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Eperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Pinaverium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aranidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09230</drugbank-id>
      <name>Azelnidipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Azelnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Benidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Cilnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09234</drugbank-id>
      <name>Darodipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Darodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09240</drugbank-id>
      <name>Niludipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Niludipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Carboxyamidotriazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Vinpocetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Gallopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Bencyclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Terodiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Lidoflazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13835</drugbank-id>
      <name>Caroverine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Caroverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with WIN 55212-2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13961</drugbank-id>
      <name>Fish oil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Fish oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aloglutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Morphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Codeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Hydromorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Meperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Oxycodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Butorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dextropropoxyphene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Pentazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Naltrexone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Sufentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Fentanyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nalbuphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Levorphanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Remifentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Hydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Diphenoxylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Oxymorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dezocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Levacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl acetate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Methadyl acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dihydroetorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Diamorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Diamorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01459</drugbank-id>
      <name>Bezitramide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Bezitramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Ethylmorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Etorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dextromoramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01531</drugbank-id>
      <name>Desomorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Desomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Carfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dihydrocodeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Alphacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dihydromorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tapentadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Ketobemidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with DPDPE.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Lofentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09272</drugbank-id>
      <name>Eluxadoline</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Eluxadoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Opium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Normethadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Piritramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Alphaprodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13454</drugbank-id>
      <name>Nicomorphine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Nicomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Meptazinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Phenoperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Phenazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tilidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15360</drugbank-id>
      <name>Carfentanil, C-11</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Carfentanil, C-11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15465</drugbank-id>
      <name>Benzhydrocodone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Benzhydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aluminium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aluminum hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Calcium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Magaldrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Magnesium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aluminium acetoacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Hydrotalcite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Almasilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aluminium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Calcium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Magnesium hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Magnesium oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Magnesium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Magnesium peroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Magnesium trisilicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00809</drugbank-id>
      <name>Tropicamide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Hexafluronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00979</drugbank-id>
      <name>Cyclopentolate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Cyclopentolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Fenoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11181</drugbank-id>
      <name>Homatropine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Homatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Butabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Butalbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Talbutal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Pentobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Metocurine iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Secobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Metharbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Dextromethorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Cisatracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Thiopental.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Procaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Atracurium besylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Isoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Methylphenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amantadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Chloroprocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aprobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Butobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Heptabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Hexobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Barbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01496</drugbank-id>
      <name>Barbituric acid derivative</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Barbituric acid derivative.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Gantacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>The risk or severity of adverse effects can be increased when Sorbitol is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04816</drugbank-id>
      <name>Dantron</name>
      <description>The risk or severity of adverse effects can be increased when Dantron is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04823</drugbank-id>
      <name>Oxyphenisatin</name>
      <description>The risk or severity of adverse effects can be increased when Oxyphenisatin is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09020</drugbank-id>
      <name>Bisacodyl</name>
      <description>The risk or severity of adverse effects can be increased when Bisacodyl is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The risk or severity of adverse effects can be increased when Picosulfuric acid is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09311</drugbank-id>
      <name>Polycarbophil</name>
      <description>The risk or severity of adverse effects can be increased when Polycarbophil is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11059</drugbank-id>
      <name>Carboxymethylcellulose</name>
      <description>The risk or severity of adverse effects can be increased when Carboxymethylcellulose is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11097</drugbank-id>
      <name>Plantago seed</name>
      <description>The risk or severity of adverse effects can be increased when Plantago seed is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11113</drugbank-id>
      <name>Castor oil</name>
      <description>The risk or severity of adverse effects can be increased when Castor oil is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11365</drugbank-id>
      <name>Sennosides</name>
      <description>The risk or severity of adverse effects can be increased when Sennosides is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12942</drugbank-id>
      <name>Lactitol</name>
      <description>The risk or severity of adverse effects can be increased when Lactitol is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The risk or severity of adverse effects can be increased when Lactulose is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The risk or severity of adverse effects can be increased when Glycerin is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11057</drugbank-id>
      <name>Mineral oil</name>
      <description>The risk or severity of adverse effects can be increased when Mineral oil is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11089</drugbank-id>
      <name>Docusate</name>
      <description>The risk or severity of adverse effects can be increased when Docusate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11228</drugbank-id>
      <name>Methylcellulose</name>
      <description>The risk or severity of adverse effects can be increased when Methylcellulose is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium citrate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13526</drugbank-id>
      <name>Pentaerithrityl</name>
      <description>The risk or severity of adverse effects can be increased when Pentaerithrityl is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13707</drugbank-id>
      <name>Sodium tartrate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium tartrate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04824</drugbank-id>
      <name>Phenolphthalein</name>
      <description>The risk or severity of adverse effects can be increased when Phenolphthalein is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>The risk or severity of adverse effects can be increased when Bisoxatin is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>The risk or severity of adverse effects can be increased when Lubiprostone is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08890</drugbank-id>
      <name>Linaclotide</name>
      <description>The risk or severity of adverse effects can be increased when Linaclotide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The risk or severity of adverse effects can be increased when Prucalopride is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The risk or severity of adverse effects can be increased when Tegaserod is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13170</drugbank-id>
      <name>Plecanatide</name>
      <description>The risk or severity of adverse effects can be increased when Plecanatide is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14232</drugbank-id>
      <name>Deacetylbisacodyl</name>
      <description>The risk or severity of adverse effects can be increased when Deacetylbisacodyl is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium cation is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01593</drugbank-id>
      <name>Zinc</name>
      <description>The risk or severity of adverse effects can be increased when Zinc is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14516</drugbank-id>
      <name>Sodium cation</name>
      <description>The risk or severity of adverse effects can be increased when Sodium cation is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14546</drugbank-id>
      <name>Sulfate ion</name>
      <description>The risk or severity of adverse effects can be increased when Sulfate ion is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14585</drugbank-id>
      <name>Plantago ovata seed</name>
      <description>The risk or severity of adverse effects can be increased when Plantago ovata seed is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09269</drugbank-id>
      <name>Phenylacetic acid</name>
      <description>The risk or severity of adverse effects can be increased when Phenylacetic acid is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09409</drugbank-id>
      <name>Magnesium acetate tetrahydrate</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium acetate tetrahydrate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09414</drugbank-id>
      <name>Dipotassium phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Dipotassium phosphate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09484</drugbank-id>
      <name>Sodium fluorophosphate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium fluorophosphate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13743</drugbank-id>
      <name>Sodium aurotiosulfate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium aurotiosulfate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13996</drugbank-id>
      <name>Magnesium acetate</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium acetate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14482</drugbank-id>
      <name>Sodium ascorbate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium ascorbate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>The risk or severity of adverse effects can be increased when Potassium sulfate is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14504</drugbank-id>
      <name>Sodium phosphate, dibasic, unspecified form</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Sodium phosphate, dibasic, unspecified form.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14627</drugbank-id>
      <name>Oxyphenisatin acetate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Oxyphenisatin acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14684</drugbank-id>
      <name>Calcium polycarbophil</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Calcium polycarbophil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07715</drugbank-id>
      <name>Emodin</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Emodin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14963</drugbank-id>
      <name>Konjac mannan</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Konjac mannan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09483</drugbank-id>
      <name>Potassium lactate</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Potassium lactate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15477</drugbank-id>
      <name>Alloin</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Alloin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15478</drugbank-id>
      <name>Frangula purshiana bark</name>
      <description>The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Frangula purshiana bark.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The risk or severity of adverse effects can be increased when Dehydrocholic acid is combined with Sodium phosphate, dibasic.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>disodium hydrogen phosphate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>Na2HPO4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>141.9588</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>141.940784382</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Na+].[Na+].OP([O-])([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>HNa2O4P</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>BNIILDVGGAEEIG-UHFFFAOYSA-L</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>83.42</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>12.41</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>5.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>1.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>293</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>4759</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20809</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>34683</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C13558</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>22625</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1060</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="1">
      <id>BE0005055</id>
      <name>Sodium-dependent phosphate transporter 1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A19450</ref-id>
            <pubmed-id>23398154</pubmed-id>
            <citation>Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q8WUM9" source="Swiss-Prot">
        <name>Sodium-dependent phosphate transporter 1</name>
        <general-function/>
        <specific-function/>
        <gene-name>SLC20A1</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>73699.01</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10946</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8WUM9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S20A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Gibbon ape leukemia virus receptor 1</synonym>
          <synonym>GLVR-1</synonym>
          <synonym>GLVR1</synonym>
          <synonym>Leukemia virus receptor 1 homolog</synonym>
          <synonym>Phosphate transporter 1</synonym>
          <synonym>PiT-1</synonym>
          <synonym>PIT1</synonym>
          <synonym>Solute carrier family 20 member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0022118|Sodium-dependent phosphate transporter 1
MATLITSTTAATAASGPLVDYLWMLILGFIIAFVLAFSVGANDVANSFGTAVGSGVVTLK
QACILASIFETVGSVLLGAKVSETIRKGLIDVEMYNSTQGLLMAGSVSAMFGSAVWQLVA
SFLKLPISGTHCIVGATIGFSLVAKGQEGVKWSELIKIVMSWFVSPLLSGIMSGILFFLV
RAFILHKADPVPNGLRALPVFYACTVGINLFSIMYTGAPLLGFDKLPLWGTILISVGCAV
FCALIVWFFVCPRMKRKIEREIKCSPSESPLMEKKNSLKEDHEETKLSVGDIENKHPVSE
VGPATVPLQAVVEERTVSFKLGDLEEAPERERLPSVDLKEETSIDSTVNGAVQLPNGNLV
QFSQAVSNQINSSGHYQYHTVHKDSGLYKELLHKLHLAKVGDCMGDSGDKPLRRNNSYTS
YTMAICGMPLDSFRAKEGEQKGEEMEKLTWPNADSKKRIRMDSYTSYCNAVSDLHSASEI
DMSVKAEMGLGDRKGSNGSLEEWYDQDKPEVSLLFQFLQILTACFGSFAHGGNDVSNAIG
PLVALYLVYDTGDVSSKVATPIWLLLYGGVGICVGLWVWGRRVIQTMGKDLTPITPSSGF
SIELASALTVVIASNIGLPISTTHCKVGSVVSVGWLRSKKAVDWRLFRNIFMAWFVTVPI
SGVISAAIMAIFRYVILRM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0022119|Sodium-dependent phosphate transporter 1 (SLC20A1)
ATGGCAACGCTGATTACCAGTACTACAGCTGCTACCGCCGCTTCTGGTCCTTTGGTGGAC
TACCTATGGATGCTCATCCTGGGCTTCATTATTGCATTTGTCTTGGCATTCTCCGTGGGA
GCCAATGATGTAGCAAATTCTTTTGGTACAGCTGTGGGCTCAGGTGTAGTGACCCTGAAG
CAAGCCTGCATCCTAGCTAGCATCTTTGAAACAGTGGGCTCTGTCTTACTGGGGGCCAAA
GTGAGCGAAACCATCCGGAAGGGCTTGATTGACGTGGAGATGTACAACTCGACTCAAGGG
CTGCTGATGGCCGGCTCAGTCAGTGCTATGTTTGGTTCTGCTGTGTGGCAACTCGTGGCT
TCGTTTTTGAAGCTCCCTATTTCTGGAACCCATTGTATTGTTGGTGCAACTATTGGTTTC
TCCCTCGTGGCAAAGGGGCAGGAGGGTGTCAAGTGGTCTGAACTGATAAAAATTGTGATG
TCTTGGTTCGTGTCCCCACTGCTTTCTGGAATTATGTCTGGAATTTTATTCTTCCTGGTT
CGTGCATTCATCCTCCATAAGGCAGATCCAGTTCCTAATGGTTTGCGAGCTTTGCCAGTT
TTCTATGCCTGCACAGTTGGAATAAACCTCTTTTCCATCATGTATACTGGAGCACCGTTG
CTGGGCTTTGACAAACTTCCTCTGTGGGGTACCATCCTCATCTCGGTGGGATGTGCAGTT
TTCTGTGCCCTTATCGTCTGGTTCTTTGTATGTCCCAGGATGAAGAGAAAAATTGAACGA
GAAATAAAGTGTAGTCCTTCTGAAAGCCCCTTAATGGAAAAAAAGAATAGCTTGAAAGAA
GACCATGAAGAAACAAAGTTGTCTGTTGGTGATATTGAAAACAAGCATCCTGTTTCTGAG
GTAGGGCCTGCCACTGTGCCCCTCCAGGCTGTGGTGGAGGAGAGAACAGTCTCATTCAAA
CTTGGAGATTTGGAGGAAGCTCCAGAGAGAGAGAGGCTTCCCAGCGTGGACTTGAAAGAG
GAAACCAGCATAGATAGCACCGTGAATGGTGCAGTGCAGTTGCCTAATGGGAACCTTGTC
CAGTTCAGTCAAGCCGTCAGCAACCAAATAAACTCCAGTGGCCACTACCAGTATCACACC
GTGCATAAGGATTCCGGCCTGTACAAAGAGCTACTCCATAAATTACATCTTGCCAAGGTG
GGAGATTGCATGGGAGACTCCGGTGACAAACCCTTAAGGCGCAATAATAGCTATACTTCC
TATACCATGGCAATATGTGGCATGCCTCTGGATTCATTCCGTGCCAAAGAAGGTGAACAG
AAGGGCGAAGAAATGGAGAAGCTGACATGGCCTAATGCAGACTCCAAGAAGCGAATTCGA
ATGGACAGTTACACCAGTTACTGCAATGCTGTGTCTGACCTTCACTCAGCATCTGAGATA
GACATGAGTGTCAAGGCAGAGATGGGTCTAGGTGACAGAAAAGGAAGTAATGGCTCTCTA
GAAGAATGGTATGACCAGGATAAGCCTGAAGTCTCTCTCCTCTTCCAGTTCCTGCAGATC
CTTACAGCCTGCTTTGGGTCATTCGCCCATGGTGGCAATGACGTAAGCAATGCCATTGGG
CCTCTGGTTGCTTTATATTTGGTTTATGACACAGGAGATGTTTCTTCAAAAGTGGCAACA
CCAATATGGCTTCTACTCTATGGTGGTGTTGGTATCTGTGTTGGTCTGTGGGTTTGGGGA
AGAAGAGTTATCCAGACCATGGGGAAGGATCTGACACCGATCACACCCTCTAGTGGCTTC
AGTATTGAACTGGCATCTGCCCTCACTGTGGTGATTGCATCAAATATTGGCCTTCCCATC
AGTACAACACATTGTAAAGTGGGCTCTGTTGTGTCTGTTGGCTGGCTCCGGTCCAAGAAG
GCTGTTGACTGGCGTCTCTTTCGTAACATTTTTATGGCCTGGTTTGTCACAGTCCCCATT
TCTGGAGTTATCAGTGCTGCCATCATGGCAATCTTCAGATATGTCATCCTCAGAATGTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01384</identifier>
            <name>PHO4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>high-affinity inorganic phosphate</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>signal transducer activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="2">
      <id>BE0008680</id>
      <name>Sodium-dependent phosphate transporter 2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A19450</ref-id>
            <pubmed-id>23398154</pubmed-id>
            <citation>Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q08357" source="Swiss-Prot">
        <name>Sodium-dependent phosphate transporter 2</name>
        <general-function>Virus receptor activity</general-function>
        <specific-function>Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular metabolism, signal transduction, and nucleic acid and lipid synthesis. In vitro, sodium-dependent phosphate uptake is not siginificantly affected by acidic and alkaline conditions, however sodium-independent phosphate uptake occurs at acidic conditions. May play a role in extracellular matrix, cartilage and vascular calcification. Functions as a retroviral receptor and confers human cells susceptibility to infection to amphotropic murine leukemia virus (A-MuLV), 10A1 murine leukemia virus (10A1 MLV) and some feline leukemia virus subgroup B (FeLV-B) variants.</specific-function>
        <gene-name>SLC20A2</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>6-26
47-67
87-107
110-130
143-163
191-211
214-234
483-503
531-551
572-586
594-609
622-642</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>70391.755</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10947</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q08357</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S20A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Gibbon ape leukemia virus receptor 2</synonym>
          <synonym>GLVR-2</synonym>
          <synonym>GLVR2</synonym>
          <synonym>hPit2</synonym>
          <synonym>Phosphate transporter 2</synonym>
          <synonym>PiT-2</synonym>
          <synonym>PIT2</synonym>
          <synonym>Solute carrier family 20 member 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049436|Sodium-dependent phosphate transporter 2
MAMDEYLWMVILGFIIAFILAFSVGANDVANSFGTAVGSGVVTLRQACILASIFETTGSV
LLGAKVGETIRKGIIDVNLYNETVETLMAGEVSAMVGSAVWQLIASFLRLPISGTHCIVG
STIGFSLVAIGTKGVQWMELVKIVASWFISPLLSGFMSGLLFVLIRIFILKKEDPVPNGL
RALPVFYAATIAINVFSIMYTGAPVLGLVLPMWAIALISFGVALLFAFFVWLFVCPWMRR
KITGKLQKEGALSRVSDESLSKVQEAESPVFKELPGAKANDDSTIPLTGAAGETLGTSEG
TSAGSHPRAAYGRALSMTHGSVKSPISNGTFGFDGHTRSDGHVYHTVHKDSGLYKDLLHK
IHIDRGPEEKPAQESNYRLLRRNNSYTCYTAAICGLPVHATFRAADSSAPEDSEKLVGDT
VSYSKKRLRYDSYSSYCNAVAEAEIEAEEGGVEMKLASELADPDQPREDPAEEEKEEKDA
PEVHLLFHFLQVLTACFGSFAHGGNDVSNAIGPLVALWLIYKQGGVTQEAATPVWLLFYG
GVGICTGLWVWGRRVIQTMGKDLTPITPSSGFTIELASAFTVVIASNIGLPVSTTHCKVG
SVVAVGWIRSRKAVDWRLFRNIFVAWFVTVPVAGLFSAAVMALLMYGILPYV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049437|Sodium-dependent phosphate transporter 2 (SLC20A2)
ATGGCCATGGATGAGTATTTGTGGATGGTCATTTTGGGTTTCATCATAGCTTTCATCTTG
GCCTTTTCTGTTGGTGCAAACGATGTTGCCAACTCCTTTGGTACAGCCGTGGGCTCTGGT
GTGGTGACCTTGAGGCAGGCATGCATTTTAGCTTCAATATTTGAAACCACCGGCTCCGTG
TTACTAGGCGCCAAAGTAGGAGAAACCATTCGCAAAGGTATCATTGACGTGAACCTGTAC
AACGAGACGGTGGAGACTCTCATGGCTGGGGAAGTTAGTGCCATGGTTGGTTCCGCTGTG
TGGCAGCTGATTGCTTCCTTCCTGAGGCTTCCAATCTCAGGAACGCACTGCATTGTGGGT
TCTACTATAGGATTCTCACTGGTCGCAATCGGTACCAAAGGTGTGCAGTGGATGGAGCTT
GTCAAGATTGTTGCTTCTTGGTTTATATCTCCACTGTTGTCTGGTTTCATGTCTGGCCTG
CTGTTTGTACTCATCAGAATTTTCATCTTAAAAAAGGAAGACCCTGTTCCCAATGGCCTC
CGGGCACTCCCAGTATTCTATGCTGCTACCATAGCAATCAATGTCTTTTCCATCATGTAC
ACAGGAGCACCAGTGCTCGGCCTTGTTCTCCCCATGTGGGCCATAGCCCTCATTTCCTTT
GGTGTCGCCCTCCTGTTCGCTTTTTTTGTGTGGCTCTTCGTGTGTCCGTGGATGCGGAGG
AAAATAACAGGCAAATTACAAAAAGAAGGTGCTTTATCACGAGTATCTGACGAAAGCCTC
AGTAAGGTTCAGGAAGCAGAGTCCCCAGTATTTAAAGAGCTACCAGGTGCCAAGGCTAAT
GATGACAGCACCATCCCGCTCACGGGAGCAGCAGGGGAGACACTGGGGACCTCGGAAGGC
ACTTCTGCGGGCAGCCACCCTCGGGCTGCATACGGAAGAGCACTGTCCATGACCCATGGC
TCTGTGAAATCGCCCATCTCCAACGGCACCTTCGGCTTCGACGGCCACACCAGGAGCGAC
GGTCATGTGTACCACACCGTGCACAAAGACTCGGGGCTCTACAAAGATCTGCTGCACAAA
ATCCACATCGACAGGGGCCCCGAGGAGAAGCCAGCCCAGGAAAGCAACTACCGGCTGCTG
CGCCGAAACAACAGTTACACCTGCTACACCGCAGCCATTTGTGGGCTGCCAGTGCACGCC
ACCTTTCGAGCTGCGGACTCATCGGCCCCAGAGGACAGTGAGAAGCTGGTGGGCGACACC
GTGTCCTACTCCAAGAAGAGGCTGCGCTACGACAGCTACTCGAGCTACTGTAACGCGGTG
GCAGAGGCGGAGATCGAGGCGGAGGAGGGCGGCGTGGAGATGAAGCTGGCGTCGGAGCTG
GCCGACCCTGACCAGCCGCGAGAGGACCCTGCAGAGGAGGAGAAGGAGGAGAAGGACGCA
CCCGAGGTTCACCTCCTGTTCCATTTCCTGCAGGTCCTCACCGCCTGTTTCGGGTCCTTT
GCTCACGGCGGCAATGACGTGAGTAATGCCATCGGTCCCCTGGTAGCCTTGTGGCTGATT
TACAAACAAGGCGGGGTAACGCAAGAAGCAGCTACACCCGTCTGGCTGCTGTTTTATGGA
GGAGTTGGAATCTGCACAGGCCTCTGGGTCTGGGGGAGAAGAGTGATCCAGACCATGGGG
AAGGACCTCACTCCCATCACGCCGTCCAGCGGCTTCACGATCGAGCTGGCCTCAGCCTTC
ACAGTGGTGATCGCCTCCAACATCGGGCTTCCAGTCAGCACCACGCACTGTAAGGTGGGC
TCGGTGGTGGCCGTGGGCTGGATCCGCTCCCGCAAGGCTGTGGACTGGCGCCTCTTTCGG
AACATCTTCGTGGCCTGGTTCGTGACCGTCCCTGTGGCTGGGCTGTTCAGCGCTGCTGTC
ATGGCTCTTCTCATGTATGGGATCCTTCCATATGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01384</identifier>
            <name>PHO4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-dependent phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>virus receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="3">
      <id>BE0008681</id>
      <name>Sodium-dependent phosphate transport protein 2A</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A19450</ref-id>
            <pubmed-id>23398154</pubmed-id>
            <citation>Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q06495" source="Swiss-Prot">
        <name>Sodium-dependent phosphate transport protein 2A</name>
        <general-function>Sodium:phosphate symporter activity</general-function>
        <specific-function>Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.</specific-function>
        <gene-name>SLC34A1</gene-name>
        <locus/>
        <cellular-location>Apical cell membrane</cellular-location>
        <transmembrane-regions>104-125
146-163
166-185
348-370
413-436
467-487
514-534
540-561</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>68936.53</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11019</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q06495</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NPT2A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Na(+)-dependent phosphate cotransporter 2A</synonym>
          <synonym>Na(+)/Pi cotransporter 2A</synonym>
          <synonym>NaPi-2a</synonym>
          <synonym>NaPi-3</synonym>
          <synonym>NPT2</synonym>
          <synonym>SLC17A2</synonym>
          <synonym>Sodium-phosphate transport protein 2A</synonym>
          <synonym>Sodium/phosphate cotransporter 2A</synonym>
          <synonym>Solute carrier family 34 member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049438|Sodium-dependent phosphate transport protein 2A
MLSYGERLGSPAVSPLPVRGGHVMRGTAFAYVPSPQVLHRIPGTSAYAFPSLGPVALAEH
TCPCGEVLERHEPLPAKLALEEEQKPESRLVPKLRQAGAMLLKVPLMLTFLYLFVCSLDM
LSSAFQLAGGKVAGDIFKDNAILSNPVAGLVVGILVTVLVQSSSTSTSIIVSMVSSGLLE
VSSAIPIIMGSNIGTSVTNTIVALMQAGDRTDFRRAFAGATVHDCFNWLSVLVLLPLEAA
TGYLHHITRLVVASFNIHGGRDAPDLLKIITEPFTKLIIQLDESVITSIATGDESLRNHS
LIQIWCHPDSLQAPTSMSRAEANSSQTLGNATMEKCNHIFVDTGLPDLAVGLILLAGSLV
LLCTCLILLVKMLNSLLKGQVAKVIQKVINTDFPAPFTWVTGYFAMVVGASMTFVVQSSS
VFTSAITPLIGLGVISIERAYPLTLGSNIGTTTTAILAALASPREKLSSAFQIALCHFFF
NISGILLWYPVPCTRLPIRMAKALGKRTAKYRWFAVLYLLVCFLLLPSLVFGISMAGWQV
MVGVGTPFGALLAFVVLINVLQSRSPGHLPKWLQTWDFLPRWMHSLKPLDHLITRATLCC
ARPEPRSPPLPPRVFLEELPPATPSPRLALPAHHNATRL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049439|Sodium-dependent phosphate transport protein 2A (SLC34A1)
ATGTTGTCCTACGGAGAGAGGCTGGGGTCCCCTGCTGTCTCCCCACTCCCAGTCCGTGGG
GGGCATGTGATGCGAGGGACGGCCTTTGCCTACGTGCCCAGCCCTCAGGTCCTACACAGG
ATCCCGGGGACCTCTGCCTATGCCTTCCCCAGCCTGGGCCCTGTGGCCCTTGCTGAGCAC
ACCTGCCCCTGTGGGGAGGTCCTGGAGCGCCATGAACCACTGCCTGCCAAGCTGGCCCTG
GAGGAGGAGCAGAAGCCAGAGTCCAGGCTGGTCCCCAAGCTGCGCCAGGCTGGCGCCATG
CTGCTCAAGGTGCCACTGATGCTCACCTTCCTCTACCTCTTCGTCTGCTCCCTGGACATG
CTCAGCTCGGCCTTCCAGCTGGCTGGAGGGAAGGTGGCTGGTGACATCTTCAAGGATAAC
GCCATCCTGTCCAACCCGGTGGCCGGGCTGGTGGTGGGGATCCTGGTGACCGTGCTGGTG
CAGAGCTCCAGCACCTCCACATCCATCATCGTCAGCATGGTCTCCTCTGGCTTGCTGGAG
GTGAGCTCTGCCATCCCCATCATCATGGGCTCCAACATCGGCACCTCTGTCACCAACACC
ATCGTGGCCCTGATGCAGGCGGGGGACAGGACTGACTTCCGGCGGGCCTTCGCGGGGGCC
ACGGTGCATGACTGCTTTAACTGGCTGTCAGTGCTGGTCCTGCTGCCCCTGGAGGCTGCC
ACTGGCTACCTGCACCACATCACTCGACTTGTGGTGGCCTCCTTCAACATCCATGGTGGC
CGTGATGCTCCTGACCTGCTCAAGATCATCACAGAGCCCTTCACGAAGCTCATCATCCAG
CTGGACGAGTCTGTGATAACCAGCATTGCCACTGGTGATGAGTCCCTGAGGAACCACAGT
CTCATCCAGATCTGGTGCCACCCAGACTCCTTACAGGCTCCCACCTCCATGTCCAGAGCA
GAGGCCAACTCCAGCCAGACCCTTGGAAATGCCACCATGGAGAAATGCAACCACATCTTT
GTGGACACTGGCCTACCGGACCTGGCTGTGGGGCTCATCCTGCTGGCAGGATCCCTGGTG
CTGCTGTGCACCTGCCTCATCCTCCTAGTCAAGATGCTCAACTCCCTGCTCAAGGGCCAA
GTGGCCAAGGTCATCCAGAAGGTCATCAATACGGACTTCCCTGCCCCCTTCACCTGGGTC
ACAGGCTACTTTGCCATGGTGGTGGGCGCCAGCATGACCTTCGTGGTCCAGAGCAGTTCT
GTGTTCACCTCGGCCATCACCCCACTCATCGGTCTTGGTGTGATCAGCATTGAGAGGGCC
TACCCGCTCACACTGGGTTCCAACATCGGCACCACCACCACGGCCATCCTGGCTGCCCTG
GCCAGCCCCAGGGAGAAGCTGTCCAGCGCTTTCCAGATTGCCCTCTGTCACTTCTTCTTC
AACATCTCGGGTATCCTTCTGTGGTACCCGGTGCCCTGCACACGCCTGCCCATCCGCATG
GCCAAGGCGCTGGGGAAACGCACGGCCAAGTACCGCTGGTTTGCCGTCCTCTATCTCCTT
GTCTGCTTCCTGCTGCTGCCCTCACTGGTGTTTGGCATCTCCATGGCAGGCTGGCAGGTC
ATGGTAGGTGTGGGCACGCCCTTCGGGGCCCTGCTGGCCTTCGTGGTGCTCATCAATGTC
CTGCAGAGTCGGAGTCCCGGGCACCTGCCCAAGTGGTTACAGACATGGGACTTCCTGCCT
CGCTGGATGCACTCCCTGAAGCCCCTGGACCACCTCATCACCCGCGCCACCCTATGCTGT
GCCAGGCCTGAGCCCCGCTCACCCCCGCTGCCCCCCAGGGTCTTCCTGGAGGAGCTACCC
CCTGCCACACCCTCCCCCCGTCTTGCACTGCCTGCTCACCACAATGCCACCCGCCTCTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02690</identifier>
            <name>Na_Pi_cotrans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>PDZ domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein complex binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-dependent phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arsenate ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular phosphate ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to metal ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to parathyroid hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to staurosporine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dentinogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gentamycin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>indole metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>kidney development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ossification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphate transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of sodium-dependent phosphate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to growth hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lead ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to magnesium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to mercury ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to potassium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to thyroid hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tricarboxylic acid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="4">
      <id>BE0008682</id>
      <name>Sodium-dependent phosphate transport protein 2B</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A19450</ref-id>
            <pubmed-id>23398154</pubmed-id>
            <citation>Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="O95436" source="Swiss-Prot">
        <name>Sodium-dependent phosphate transport protein 2B</name>
        <general-function>Sodium:phosphate symporter activity</general-function>
        <specific-function>May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant in lungs' alveoli.</specific-function>
        <gene-name>SLC34A2</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>101-121
136-156
213-233
363-383
408-428
486-506
526-546
553-573</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>75758.535</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11020</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O95436</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NPT2B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Na(+)-dependent phosphate cotransporter 2B</synonym>
          <synonym>Na(+)/Pi cotransporter 2B</synonym>
          <synonym>NaPi-2b</synonym>
          <synonym>NaPi3b</synonym>
          <synonym>Sodium-phosphate transport protein 2B</synonym>
          <synonym>Sodium/phosphate cotransporter 2B</synonym>
          <synonym>Solute carrier family 34 member 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049440|Sodium-dependent phosphate transport protein 2B
MAPWPELGDAQPNPDKYLEGAAGQQPTAPDKSKETNKTDNTEAPVTKIELLPSYSTATLI
DEPTEVDDPWNLPTLQDSGIKWSERDTKGKILCFFQGIGRLILLLGFLYFFVCSLDILSS
AFQLVGGKMAGQFFSNSSIMSNPLLGLVIGVLVTVLVQSSSTSTSIVVSMVSSSLLTVRA
AIPIIMGANIGTSITNTIVALMQVGDRSEFRRAFAGATVHDFFNWLSVLVLLPVEVATHY
LEIITQLIVESFHFKNGEDAPDLLKVITKPFTKLIVQLDKKVISQIAMNDEKAKNKSLVK
IWCKTFTNKTQINVTVPSTANCTSPSLCWTDGIQNWTMKNVTYKENIAKCQHIFVNFHLP
DLAVGTILLILSLLVLCGCLIMIVKILGSVLKGQVATVIKKTINTDFPFPFAWLTGYLAI
LVGAGMTFIVQSSSVFTSALTPLIGIGVITIERAYPLTLGSNIGTTTTAILAALASPGNA
LRSSLQIALCHFFFNISGILLWYPIPFTRLPIRMAKGLGNISAKYRWFAVFYLIIFFFLI
PLTVFGLSLAGWRVLVGVGVPVVFIIILVLCLRLLQSRCPRVLPKKLQNWNFLPLWMRSL
KPWDAVVSKFTGCFQMRCCCCCRVCCRACCLLCDCPKCCRCSKCCEDLEEAQEGQDVPVK
APETFDNITISREAQGEVPASDSKTECTAL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049441|Sodium-dependent phosphate transport protein 2B (SLC34A2)
ATGGCTCCCTGGCCTGAATTGGGAGATGCCCAGCCCAACCCCGATAAGTACCTCGAAGGG
GCCGCAGGTCAGCAGCCCACTGCCCCTGATAAAAGCAAAGAGACCAACAAAACAGATAAC
ACTGAGGCACCTGTAACCAAGATTGAACTTCTGCCGTCCTACTCCACGGCTACACTGATA
GATGAGCCCACTGAGGTGGATGACCCCTGGAACCTACCCACTCTTCAGGACTCGGGGATC
AAGTGGTCAGAGAGAGACACCAAAGGGAAGATTCTCTGTTTCTTCCAAGGGATTGGGAGA
TTGATTTTACTTCTCGGATTTCTCTACTTTTTCGTGTGCTCCCTGGATATTCTTAGTAGC
GCCTTCCAGCTGGTTGGAGGAAAAATGGCAGGACAGTTCTTCAGCAACAGCTCTATTATG
TCCAACCCTTTGTTGGGGCTGGTGATCGGGGTGCTGGTGACCGTCTTGGTGCAGAGCTCC
AGCACCTCAACGTCCATCGTTGTCAGCATGGTGTCCTCTTCATTGCTCACTGTTCGGGCT
GCCATCCCCATTATCATGGGGGCCAACATTGGAACGTCAATCACCAACACTATTGTTGCG
CTCATGCAGGTGGGAGATCGGAGTGAGTTCAGAAGAGCTTTTGCAGGAGCCACTGTCCAT
GACTTCTTCAACTGGCTGTCCGTGTTGGTGCTCTTGCCCGTGGAGGTGGCCACCCATTAC
CTCGAGATCATAACCCAGCTTATAGTGGAGAGCTTCCACTTCAAGAATGGAGAAGATGCC
CCAGATCTTCTGAAAGTCATCACTAAGCCCTTCACAAAGCTCATTGTCCAGCTGGATAAA
AAAGTTATCAGCCAAATTGCAATGAACGATGAAAAAGCGAAAAACAAGAGTCTTGTCAAG
ATTTGGTGCAAAACTTTTACCAACAAGACCCAGATTAACGTCACTGTTCCCTCGACTGCT
AACTGCACCTCCCCTTCCCTCTGTTGGACGGATGGCATCCAAAACTGGACCATGAAGAAT
GTGACCTACAAGGAGAACATCGCCAAATGCCAGCATATCTTTGTGAATTTCCACCTCCCG
GATCTTGCTGTGGGCACCATCTTGCTCATACTCTCCCTGCTGGTCCTCTGTGGTTGCCTG
ATCATGATTGTCAAGATCCTGGGCTCTGTGCTCAAGGGGCAGGTCGCCACTGTCATCAAG
AAGACCATCAACACTGATTTCCCCTTTCCCTTTGCATGGTTGACTGGCTACCTGGCCATC
CTCGTCGGGGCAGGCATGACCTTCATCGTACAGAGCAGCTCTGTGTTCACGTCGGCCTTG
ACCCCCCTGATTGGAATCGGCGTGATAACCATTGAGAGGGCTTATCCACTCACGCTGGGC
TCCAACATCGGCACCACCACCACCGCCATCCTGGCCGCCTTAGCCAGCCCTGGCAATGCA
TTGAGGAGTTCACTCCAGATCGCCCTGTGCCACTTTTTCTTCAACATCTCCGGCATCTTG
CTGTGGTACCCGATCCCGTTCACTCGCCTGCCCATCCGCATGGCCAAGGGGCTGGGCAAC
ATCTCTGCCAAGTATCGCTGGTTCGCCGTCTTCTACCTGATCATCTTCTTCTTCCTGATC
CCGCTGACGGTGTTTGGCCTCTCGCTGGCCGGCTGGCGGGTGCTGGTTGGTGTCGGGGTT
CCCGTCGTCTTCATCATCATCCTGGTACTGTGCCTCCGACTCCTGCAGTCTCGCTGCCCA
CGCGTCCTGCCGAAGAAACTCCAGAACTGGAACTTCCTGCCGCTGTGGATGCGCTCGCTG
AAGCCCTGGGATGCCGTCGTCTCCAAGTTCACCGGCTGCTTCCAGATGCGCTGCTGCTGC
TGCTGCCGCGTGTGCTGCCGCGCGTGCTGCTTGCTGTGTGGCTGCCCCAAGTGCTGCCGC
TGCAGCAAGTGCTGCGAGGACTTGGAGGAGGCGCAGGAGGGGCAGGATGTCCCTGTCAAG
GCTCCTGAGACCTTTGATAACATAACCATTAGCAGAGAGGCTCAGGGTGAGGTCCCTGCC
TCGGACTCAAAGACCGAATGCACGGCCTTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02690</identifier>
            <name>Na_Pi_cotrans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphate ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-dependent phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular phosphate ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>in utero embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="5">
      <id>BE0008683</id>
      <name>Sodium-dependent phosphate transport protein 2C</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1950</ref-id>
            <pubmed-id>12360109</pubmed-id>
            <citation>Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q8N130" source="Swiss-Prot">
        <name>Sodium-dependent phosphate transport protein 2C</name>
        <general-function>Sodium:phosphate symporter activity</general-function>
        <specific-function>May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.</specific-function>
        <gene-name>SLC34A3</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>77-97
112-132
189-209
323-343
368-388
446-466
486-506
511-531</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>63548.94</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:20305</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8N130</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NPT2C_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Na(+)-dependent phosphate cotransporter 2C</synonym>
          <synonym>Na(+)/Pi cotransporter 2C</synonym>
          <synonym>NaPi-2c</synonym>
          <synonym>NPT2C</synonym>
          <synonym>NPTIIC</synonym>
          <synonym>Sodium-phosphate transport protein 2C</synonym>
          <synonym>Sodium/inorganic phosphate cotransporter IIC</synonym>
          <synonym>Sodium/phosphate cotransporter 2C</synonym>
          <synonym>Solute carrier family 34 member 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049442|Sodium-dependent phosphate transport protein 2C
MPSSLPGSQVPHPTLDAVDLVEKTLRNEGTSSSAPVLEEGDTDPWTLPQLKDTSQPWKEL
RVAGRLRRVAGSVLKACGLLGSLYFFICSLDVLSSAFQLLGSKVAGDIFKDNVVLSNPVA
GLVIGVLVTALVQSSSTSSSIVVSMVAAKLLTVRVSVPIIMGVNVGTSITSTLVSMAQSG
DRDEFQRAFSGSAVHGIFNWLTVLVLLPLESATALLERLSELALGAASLTPRAQAPDILK
VLTKPLTHLIVQLDSDMIMSSATGNATNSSLIKHWCGTTGQPTQENSSCGAFGPCTEKNS
TAPADRLPCRHLFAGTELTDLAVGCILLAGSLLVLCGCLVLIVKLLNSVLRGRVAQVVRT
VINADFPFPLGWLGGYLAVLAGAGLTFALQSSSVFTAAVVPLMGVGVISLDRAYPLLLGS
NIGTTTTALLAALASPADRMLSALQVALIHFFFNLAGILLWYLVPALRLPIPLARHFGVV
TARYRWVAGVYLLLGFLLLPLAAFGLSLAGGMELAAVGGPLVGLVLLVILVTVLQRRRPA
WLPVRLRSWAWLPVWLHSLEPWDRLVTRCCPCNVCSPPKATTKEAYCYENPEILASQQL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049443|Sodium-dependent phosphate transport protein 2C (SLC34A3)
ATGCCGAGTTCCCTTCCCGGCAGCCAGGTCCCCCACCCCACTCTGGACGCGGTTGACCTA
GTGGAAAAGACTCTGAGGAATGAAGGGACCTCCAGTTCTGCTCCAGTCTTGGAGGAAGGG
GACACAGACCCCTGGACCCTCCCTCAGCTGAAGGACACAAGCCAGCCCTGGAAAGAGCTC
CGCGTGGCCGGCAGGCTGCGCCGCGTGGCCGGCAGCGTCCTCAAGGCCTGCGGGCTCCTC
GGCAGCCTGTACTTCTTCATCTGCTCTCTGGACGTCCTCAGCTCCGCCTTCCAGCTGCTG
GGCAGCAAAGTGGCCGGAGACATCTTCAAGGACAACGTGGTGCTGTCCAACCCTGTGGCT
GGACTGGTCATTGGCGTGCTGGTCACAGCCCTGGTGCAGAGTTCCAGCACGTCCTCCTCC
ATCGTGGTCAGCATGGTGGCTGCTAAGCTGCTGACTGTCCGGGTGTCTGTGCCCATCATC
ATGGGTGTCAACGTAGGCACATCCATCACCAGCACCCTGGTCTCAATGGCGCAGTCAGGG
GACCGGGATGAATTTCAGAGGGCTTTCAGCGGCTCGGCGGTGCACGGGATCTTCAACTGG
CTCACAGTGCTGGTCCTGCTGCCACTGGAGAGCGCCACGGCCCTGCTGGAGAGGCTAAGT
GAGCTAGCCCTGGGTGCCGCCAGCCTGACACCCAGGGCGCAGGCGCCCGACATCCTCAAG
GTGCTGACGAAGCCGCTCACACACCTCATCGTGCAGTTGGACTCCGACATGATCATGAGC
AGTGCCACAGGCAACGCCACTAACAGCAGTCTCATTAAGCACTGGTGCGGCACCACGGGG
CAGCCGACCCAGGAGAACAGCAGCTGTGGCGCCTTCGGCCCGTGCACAGAGAAGAACAGC
ACAGCCCCGGCGGACAGGCTGCCCTGCCGCCACCTGTTTGCGGGCACGGAGCTCACGGAC
CTGGCCGTGGGCTGCATCCTGCTGGCCGGCTCCCTGCTGGTGCTCTGCGGCTGCCTGGTC
CTCATAGTCAAGCTGCTCAACTCTGTGCTGCGCGGCCGCGTGGCCCAGGTCGTGAGGACA
GTCATCAATGCGGACTTCCCCTTCCCGCTGGGCTGGCTCGGCGGCTACCTGGCCGTCCTC
GCGGGCGCCGGCCTGACCTTCGCACTGCAGAGCAGCAGCGTCTTCACGGCGGCCGTCGTG
CCCCTCATGGGGGTCGGGGTGATCAGTCTGGACCGGGCGTACCCCCTCTTACTGGGCTCC
AACATCGGCACCACTACCACAGCCCTGCTGGCTGCCCTGGCCAGCCCCGCAGACAGGATG
CTCAGCGCCCTGCAGGTCGCCCTCATCCACTTCTTCTTCAACCTGGCCGGCATCCTGCTG
TGGTACCTGGTGCCTGCACTGCGGCTGCCCATCCCGCTGGCCAGGCACTTCGGGGTGGTG
ACCGCCCGTTACCGCTGGGTGGCTGGGGTCTACCTGCTGCTCGGATTCCTGCTGCTGCCC
CTGGCGGCCTTCGGGCTCTCCCTGGCAGGGGGCATGGTGCTGGCCGCTGTCGGGGGTCCC
CTGGTGGGGCTGGTGCTCCTCGTCATCCTGGTTACTGTCCTGCAGCGGCGCCGGCCGGCC
TGGCTGCCTGTCCGCCTGCGCTCCTGGGCCTGGCTCCCCGTCTGGCTCCATTCTCTGGAG
CCCTGGGACCGCCTGGTGACCCGCTGCTGCCCCTGCAACGTCTGCAGCCCCCCGAAGGCC
ACCACCAAAGAGGCCTACTGCTACGAGAACCCTGAGATCTTGGCCTCCCAGCAGTTGTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02690</identifier>
            <name>Na_Pi_cotrans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-dependent phosphate transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular phosphate ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphate ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>